Hematologic Malignancy Working Group


Dr. Richard Ambinder, Johns Hopkins University
Hematologic Malignancy Working Group Chair


Dr. Erin Reid, University of California, San Diego
Hematologic Malignancy Working Group Vice Chair

The AMC has implemented and completed several seminal studies which have clearly changed the way in which patients with HIV associated lymphoma are treated, moving the field forward in a step-wise manner over the years.    Research has included studies of first line therapy in diffuse large B cell lymphoma, Burkitt lymphoma and Hodgkin lymphoma.   Studies in the relapsed and refractory setting have included second line therapy as well as autologous and allogeneic transplant.  Partnerships have been formed with other groups nationally and internationally.   The findings of the HMWG have influenced ASCO and National Comprehensive Network Guidelines (Reference).

Goals of the Hematologic Malignancy WG are to:

  1. Determine the optimal treatment of patients with HIV associated Hodgkin’s and non-Hodgkin’s lymphoma, within the context of concurrent highly active anti-retroviral therapy.
  2. Determine biologic correlates of disease, survival and response to therapy in patients with HIV associated lymphomas, to ascertain future targets for development and testing of innovative new therapies for affected patients.
  3. Determine any biologic or clinical differences between AIDS-related Burkitt’s lymphoma when diagnosed in the USA versus other regions of the world.

Current Protocols:

AMC-068 Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa
AMC-085 A Phase 1/2 Study Examining AVD and Brentuximab Vedotin in Patients with HIV and Advanced Stage Hodgkin's Lymphoma
AMC-097 A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells
AMC-101 Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
AMC-S004 Clinical and Genomic Factors for Prognosis of Primary Effusion Lymphoma

List of Completed Studies:

Closure Date
AMC-053 Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with Relapsed/ Refractory AIDS-Associated Non-Hodgkin’s Lymphoma
AMC-075 A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-cell Non-Hodgkin’s Lymphoma
AMC-080 / BMT CTN 0903 Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
AMC-086 / 9177 Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma